NEUROCRINE BIOSCIENCES INC Net Income
NEUROCRINE BIOSCIENCES INC (NBIX) reported Net Income of $144.40 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLoss · last filed 2026-07-31
- NEUROCRINE BIOSCIENCES INC net income (loss) attributable to parent for the quarter ending 2026-06-30 was $144.40M, a 34.33% increase year-over-year.
- NEUROCRINE BIOSCIENCES INC net income (loss) attributable to parent for the quarter ending 2026-03-31 was $197.90M, a 2405.06% increase year-over-year.
- NEUROCRINE BIOSCIENCES INC net income (loss) attributable to parent for the quarter ending 2025-12-31 was $153.70M, a 49.08% increase year-over-year.
- NEUROCRINE BIOSCIENCES INC net income (loss) attributable to parent for the quarter ending 2025-09-30 was $209.50M, a 61.40% increase year-over-year.
- NEUROCRINE BIOSCIENCES INC net income (loss) attributable to parent for fiscal 2020 was $407.30M, a 1000.81% increase from fiscal 2019.
- NEUROCRINE BIOSCIENCES INC net income (loss) attributable to parent for fiscal 2019 was $37.00M, a 75.36% increase from fiscal 2018.
- NEUROCRINE BIOSCIENCES INC net income (loss) attributable to parent for fiscal 2018 was $21.10M.
- NEUROCRINE BIOSCIENCES INC net income (loss) attributable to parent for fiscal 2017 was -$142.54M.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 3 month as first filed | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 6 month as first filed | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 9 month as first filed | Net Income (Loss) Attributable to Parent 12 month | Net Income (Loss) Attributable to Parent 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $144.40M 10-Q · filed 2026-07-31 | $342.30M 10-Q · filed 2026-07-31 | $496.00M derived: sum of 3 quarters · filed 2026-07-31 | $705.50M derived: sum of 4 quarters · filed 2026-07-31 | ||||
| 2026-03-31 | $197.90M 10-Q · filed 2026-05-05 | $351.60M derived: sum of 2 quarters · filed 2026-05-05 | $561.10M derived: sum of 3 quarters · filed 2026-05-05 | $668.60M derived: sum of 4 quarters · filed 2026-07-31 | ||||
| 2025-12-31 | $153.70M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-15 | $363.20M derived: sum of 2 quarters · filed 2026-04-15 | $470.70M derived: sum of 3 quarters · filed 2026-07-31 | $478.60M DEF 14A · filed 2026-04-15 | ||||
| 2025-09-30 | $209.50M 10-Q · filed 2025-10-28 | $317.00M derived: sum of 2 quarters · filed 2026-07-31 | $324.90M 10-Q · filed 2025-10-28 | $428.00M derived: sum of 4 quarters · filed 2026-07-31 | ||||
| 2025-06-30 | $107.50M 10-Q · filed 2026-07-31 | $115.40M 10-Q · filed 2026-07-31 | $218.50M derived: sum of 3 quarters · filed 2026-07-31 | $348.30M derived: sum of 4 quarters · filed 2026-07-31 | ||||
| 2025-03-31 | $7.90M 10-Q · filed 2026-05-05 | $111.00M derived: sum of 2 quarters · filed 2026-05-05 | $240.80M derived: sum of 3 quarters · filed 2026-05-05 | $305.80M derived: sum of 4 quarters · filed 2026-05-05 | ||||
| 2024-12-31 | $103.10M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-15 | $232.90M derived: sum of 2 quarters · filed 2026-04-15 | $297.90M derived: sum of 3 quarters · filed 2026-04-15 | $341.30M DEF 14A · filed 2026-04-15 | ||||
| 2024-09-30 | $129.80M 10-Q · filed 2025-10-28 | $194.80M derived: sum of 2 quarters · filed 2025-10-28 | $238.20M 10-Q · filed 2025-10-28 | $385.90M derived: sum of 4 quarters · filed 2026-04-15 | ||||
| 2024-06-30 | $65.00M 10-Q · filed 2025-07-30 | $108.40M 10-Q · filed 2025-07-30 | $256.10M derived: sum of 3 quarters · filed 2026-04-15 | $339.20M derived: sum of 4 quarters · filed 2026-04-15 | ||||
| 2024-03-31 | $43.40M 10-Q · filed 2025-05-05 | $191.10M derived: sum of 2 quarters · filed 2026-04-15 | $274.20M derived: sum of 3 quarters · filed 2026-04-15 | $369.70M derived: sum of 4 quarters · filed 2026-04-15 | ||||
| 2023-12-31 | $147.70M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-15 | $230.80M derived: sum of 2 quarters · filed 2026-04-15 | $326.30M derived: sum of 3 quarters · filed 2026-04-15 | $249.70M DEF 14A · filed 2026-04-15 | ||||
| 2023-09-30 | $83.10M 10-Q · filed 2024-10-30 | $178.60M derived: sum of 2 quarters · filed 2024-10-30 | $102.00M 10-Q · filed 2024-10-30 | $191.00M derived: sum of 4 quarters · filed 2026-04-15 | ||||
| 2023-06-30 | $95.50M 10-Q · filed 2024-08-01 | $18.90M 10-Q · filed 2024-08-01 | $107.90M derived: sum of 3 quarters · filed 2026-04-15 | $176.40M derived: sum of 4 quarters · filed 2026-04-15 | ||||
| 2023-03-31 | -$76.60M 10-Q · filed 2024-05-01 | $12.40M derived: sum of 2 quarters · filed 2026-04-15 | $80.90M derived: sum of 3 quarters · filed 2026-04-15 | $64.00M derived: sum of 4 quarters · filed 2026-04-15 | ||||
| 2022-12-31 | $89.00M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-15 | $157.50M derived: sum of 2 quarters · filed 2026-04-15 | $140.60M derived: sum of 3 quarters · filed 2026-04-15 | $154.50M DEF 14A · filed 2026-04-15 | ||||
| 2022-09-30 | $68.50M 10-Q · filed 2023-10-31 | $51.60M derived: sum of 2 quarters · filed 2023-10-31 | $65.50M 10-Q · filed 2023-10-31 | $58.20M derived: sum of 4 quarters · filed 2026-04-15 | ||||
| 2022-06-30 | -$16.90M 10-Q · filed 2023-08-01 | -$3.00M 10-Q · filed 2023-08-01 | -$10.30M derived: sum of 3 quarters · filed 2026-04-15 | $12.20M derived: sum of 4 quarters · filed 2026-04-15 | ||||
| 2022-03-31 | $13.90M 10-Q · filed 2023-05-03 | $6.60M derived: sum of 2 quarters · filed 2026-04-15 | $29.10M derived: sum of 3 quarters · filed 2026-04-15 | $71.40M derived: sum of 4 quarters · filed 2026-04-15 | ||||
| 2021-12-31 | -$7.30M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-15 | $15.20M derived: sum of 2 quarters · filed 2026-04-15 | $57.50M derived: sum of 3 quarters · filed 2026-04-15 | $89.60M DEF 14A · filed 2026-04-15 | ||||
| 2021-09-30 | $22.50M 10-Q · filed 2022-11-01 | $64.80M derived: sum of 2 quarters · filed 2022-11-01 | $96.90M 10-Q · filed 2022-11-01 | $444.80M derived: sum of 4 quarters · filed 2022-11-01 | ||||
| 2021-06-30 | $42.30M 10-Q · filed 2022-08-04 | $74.40M 10-Q · filed 2022-08-04 | $422.30M derived: sum of 3 quarters · filed 2022-08-04 | $364.70M derived: sum of 4 quarters · filed 2022-08-04 | ||||
| 2021-03-31 | $32.10M 10-Q · filed 2022-05-04 | $380.00M derived: sum of 2 quarters · filed 2022-05-04 | $322.40M derived: sum of 3 quarters · filed 2022-05-04 | $402.00M derived: sum of 4 quarters · filed 2022-05-04 | ||||
| 2020-12-31 | $347.90M 10-K · filed 2021-02-05 | $290.30M derived: sum of 2 quarters · filed 2021-11-01 | $369.90M derived: sum of 3 quarters · filed 2021-11-01 | $407.30M 10-K · filed 2023-02-09 | ||||
| 2020-09-30 | -$57.60M 10-Q · filed 2021-11-01 | $22.00M derived: sum of 2 quarters · filed 2021-11-01 | $59.40M 10-Q · filed 2021-11-01 | $93.40M derived: sum of 4 quarters · filed 2021-11-01 | ||||
| 2020-06-30 | $79.60M 10-Q · filed 2021-08-03 | $117.00M 10-Q · filed 2021-08-03 | $151.00M derived: sum of 3 quarters · filed 2021-08-03 | $204.80M derived: sum of 4 quarters · filed 2021-08-03 | ||||
| 2020-03-31 | $37.40M 10-Q · filed 2021-05-05 | $71.40M derived: sum of 2 quarters · filed 2021-05-05 | $125.20M derived: sum of 3 quarters · filed 2021-05-05 | $176.50M derived: sum of 4 quarters · filed 2021-05-05 | ||||
| 2019-12-31 | $34.00M 10-K · filed 2021-02-05 | $87.80M derived: sum of 2 quarters · filed 2021-02-05 | $139.10M derived: sum of 3 quarters · filed 2021-02-05 | $37.00M 10-K · filed 2022-02-11 | $37.01M 10-K · filed 2020-02-07 | |||
| 2019-09-30 | $53.80M 10-K · filed 2021-02-05 | $53.79M 10-Q · filed 2019-11-04 | $105.10M derived: sum of 2 quarters · filed 2021-02-05 | $3.00M 10-Q · filed 2020-11-09 | $3.01M 10-Q · filed 2019-11-04 | $21.08M derived: sum of 4 quarters · filed 2021-02-05 | ||
| 2019-06-30 | $51.30M 10-K · filed 2021-02-05 | $51.34M 10-Q · filed 2019-07-29 | -$50.80M 10-Q · filed 2020-08-03 | -$50.78M 10-Q · filed 2019-07-29 | -$32.72M derived: sum of 3 quarters · filed 2021-02-05 | $18.04M derived: sum of 4 quarters · filed 2021-02-05 | ||
| 2019-03-31 | -$102.10M 10-K · filed 2021-02-05 | -$102.11M 10-Q · filed 2019-04-29 | -$84.02M derived: sum of 2 quarters · filed 2021-02-05 | -$33.26M derived: sum of 3 quarters · filed 2021-02-05 | -$39.17M derived: sum of 4 quarters · filed 2021-02-05 | |||
| 2018-12-31 | $18.08M 10-K · filed 2020-02-07 | $68.84M derived: sum of 2 quarters · filed 2020-02-07 | $62.93M derived: sum of 3 quarters · filed 2020-02-07 | $21.10M 10-K · filed 2021-02-05 | $21.11M 10-K · filed 2019-02-08 | |||
| 2018-09-30 | $50.76M 10-K · filed 2020-02-07 | $44.85M derived: sum of 2 quarters · filed 2020-02-07 | $3.03M 10-Q · filed 2019-11-04 | $9.93M derived: sum of 4 quarters · filed 2020-02-07 | ||||
| 2018-06-30 | -$5.91M 10-K · filed 2020-02-07 | -$47.73M 10-Q · filed 2019-07-29 | -$40.84M derived: sum of 3 quarters · filed 2020-02-07 | -$51.96M derived: sum of 4 quarters · filed 2020-02-07 | ||||
| 2018-03-31 | -$41.82M 10-K · filed 2020-02-07 | -$34.92M derived: sum of 2 quarters · filed 2020-02-07 | -$46.05M derived: sum of 3 quarters · filed 2020-02-07 | -$106.03M derived: sum of 4 quarters · filed 2020-02-07 | ||||
| 2017-12-31 | $6.89M 10-K · filed 2019-02-08 | -$4.23M derived: sum of 2 quarters · filed 2019-02-08 | -$64.22M derived: sum of 3 quarters · filed 2019-02-08 | -$142.54M 10-K · filed 2020-02-07 | ||||
| 2017-09-30 | -$11.13M 10-K · filed 2019-02-08 | -$71.11M derived: sum of 2 quarters · filed 2019-02-08 | -$149.44M 10-Q · filed 2018-11-05 | -$194.09M derived: sum of 4 quarters · filed 2019-02-08 | ||||
| 2017-06-30 | -$59.98M 10-K · filed 2019-02-08 | -$138.31M 10-Q · filed 2018-07-31 | -$182.97M derived: sum of 3 quarters · filed 2019-02-08 | -$219.86M derived: sum of 4 quarters · filed 2019-02-08 | ||||
| 2017-03-31 | -$78.33M 10-K · filed 2019-02-08 | -$122.98M derived: sum of 2 quarters · filed 2019-02-08 | -$159.87M derived: sum of 3 quarters · filed 2019-02-08 | -$200.15M derived: sum of 4 quarters · filed 2019-02-08 | ||||
| 2016-12-31 | -$44.66M 10-K · filed 2018-02-13 | -$81.55M derived: sum of 2 quarters · filed 2018-02-13 | -$121.83M derived: sum of 3 quarters · filed 2018-02-13 | -$141.09M 10-K · filed 2019-02-08 | ||||
| 2016-09-30 | -$36.89M 10-K · filed 2018-02-13 | -$77.17M derived: sum of 2 quarters · filed 2018-02-13 | -$96.43M 10-Q · filed 2017-11-01 | -$125.75M derived: sum of 4 quarters · filed 2018-02-13 | ||||
| 2016-06-30 | -$40.28M 10-K · filed 2018-02-13 | -$59.54M 10-Q · filed 2017-08-03 | -$88.86M derived: sum of 3 quarters · filed 2018-02-13 | -$123.29M derived: sum of 4 quarters · filed 2018-02-13 | ||||
| 2016-03-31 | -$19.26M 10-K · filed 2018-02-13 | -$48.58M derived: sum of 2 quarters · filed 2018-02-13 | -$83.01M derived: sum of 3 quarters · filed 2018-02-13 | -$107.00M derived: sum of 4 quarters · filed 2018-02-13 | ||||
| 2015-12-31 | -$29.32M 10-K · filed 2017-02-14 | -$63.75M derived: sum of 2 quarters · filed 2017-02-14 | -$87.74M derived: sum of 3 quarters · filed 2017-02-14 | -$88.93M 10-K · filed 2018-02-13 | ||||
| 2015-09-30 | -$34.44M 10-K · filed 2017-02-14 | -$58.42M derived: sum of 2 quarters · filed 2017-02-14 | -$59.61M 10-Q · filed 2016-11-02 | -$79.06M derived: sum of 4 quarters · filed 2017-02-14 | ||||
| 2015-06-30 | -$23.99M 10-K · filed 2017-02-14 | -$25.18M 10-Q · filed 2016-08-03 | -$44.62M derived: sum of 3 quarters · filed 2017-02-14 | -$60.50M derived: sum of 4 quarters · filed 2017-02-14 | ||||
| 2015-03-31 | -$1.19M 10-K · filed 2017-02-14 | -$20.64M derived: sum of 2 quarters · filed 2017-02-14 | -$36.51M derived: sum of 3 quarters · filed 2017-02-14 | -$49.89M derived: sum of 4 quarters · filed 2017-02-14 | ||||
| 2014-12-31 | -$19.44M 10-K · filed 2016-02-11 | -$35.32M derived: sum of 2 quarters · filed 2016-02-11 | -$48.70M derived: sum of 3 quarters · filed 2016-02-11 | -$60.54M 10-K · filed 2017-02-14 | ||||
| 2014-09-30 | -$15.88M 10-K · filed 2016-02-11 | -$29.26M derived: sum of 2 quarters · filed 2016-02-11 | -$41.10M 10-Q · filed 2015-10-29 | -$51.74M derived: sum of 4 quarters · filed 2016-02-11 | ||||
| 2014-06-30 | -$13.38M 10-K · filed 2016-02-11 | -$25.22M 10-Q · filed 2015-07-29 | -$35.87M derived: sum of 3 quarters · filed 2016-02-11 | -$47.00M derived: sum of 4 quarters · filed 2016-02-11 | ||||
| 2014-03-31 | -$11.84M 10-K · filed 2016-02-11 | -$22.48M derived: sum of 2 quarters · filed 2016-02-11 | -$33.62M derived: sum of 3 quarters · filed 2016-02-11 | -$45.86M derived: sum of 4 quarters · filed 2016-02-11 | ||||
| 2013-12-31 | -$10.64M 10-K · filed 2015-02-09 | -$21.77M derived: sum of 2 quarters · filed 2015-02-09 | -$34.02M derived: sum of 3 quarters · filed 2015-02-09 | -$46.09M 10-K · filed 2016-02-11 | ||||
| 2013-09-30 | -$11.13M 10-K · filed 2015-02-09 | -$23.37M derived: sum of 2 quarters · filed 2015-02-09 | -$35.45M 10-Q · filed 2014-11-04 | -$25.96M derived: sum of 4 quarters · filed 2015-02-09 | ||||
| 2013-06-30 | -$12.24M 10-K · filed 2015-02-09 | -$24.32M 10-Q · filed 2014-08-06 | -$14.83M derived: sum of 3 quarters · filed 2015-02-09 | -$17.91M derived: sum of 4 quarters · filed 2015-02-09 | ||||
| 2013-03-31 | -$12.07M 10-K · filed 2015-02-09 | -$2.58M derived: sum of 2 quarters · filed 2015-02-09 | -$5.66M derived: sum of 3 quarters · filed 2015-02-09 | -$6.16M derived: sum of 4 quarters · filed 2015-02-09 | ||||
| 2012-12-31 | $9.49M 10-K · filed 2014-02-11 | $6.41M derived: sum of 2 quarters · filed 2014-02-11 | $5.91M derived: sum of 3 quarters · filed 2014-02-11 | $5.03M 10-K · filed 2015-02-09 | ||||
| 2012-09-30 | -$3.08M 10-K · filed 2014-02-11 | -$3.58M derived: sum of 2 quarters · filed 2014-02-11 | -$4.46M 10-Q · filed 2013-10-29 | -$3.13M derived: sum of 4 quarters · filed 2014-02-11 | ||||
| 2012-06-30 | -$501.00K 10-K · filed 2014-02-11 | -$1.39M 10-Q · filed 2013-07-26 | -$56.00K derived: sum of 3 quarters · filed 2014-02-11 | $31.33M derived: sum of 4 quarters · filed 2014-02-11 | ||||
| 2012-03-31 | -$886.00K 10-K · filed 2014-02-11 | $445.00K derived: sum of 2 quarters · filed 2014-02-11 | $31.83M derived: sum of 3 quarters · filed 2014-02-11 | $33.80M derived: sum of 4 quarters · filed 2014-02-11 | ||||
| 2011-12-31 | $1.33M 10-K · filed 2013-02-08 | $32.71M derived: sum of 2 quarters · filed 2013-02-08 | $34.69M derived: sum of 3 quarters · filed 2013-02-08 | $37.57M 10-K · filed 2014-02-11 | ||||
| 2011-09-30 | $31.38M 10-K · filed 2013-02-08 | $33.36M derived: sum of 2 quarters · filed 2013-02-08 | $36.24M 10-Q · filed 2012-10-31 | $38.73M derived: sum of 4 quarters · filed 2013-02-08 | ||||
| 2011-06-30 | $1.98M 10-K · filed 2013-02-08 | $4.86M 10-Q · filed 2012-07-31 | $7.34M derived: sum of 3 quarters · filed 2013-02-08 | $10.68M derived: sum of 4 quarters · filed 2013-02-08 | ||||
| 2011-03-31 | $2.88M 10-K · filed 2013-02-08 | $5.37M derived: sum of 2 quarters · filed 2013-02-08 | $8.70M derived: sum of 3 quarters · filed 2013-02-08 | $3.55M derived: sum of 4 quarters · filed 2013-02-08 | ||||
| 2010-12-31 | $2.49M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-08 | $5.82M derived: sum of 2 quarters · filed 2013-02-08 | $668.00K derived: sum of 3 quarters · filed 2013-02-08 | -$7.97M 10-K · filed 2013-02-08 | ||||
| 2010-09-30 | $3.33M 10-Q · filed 2011-10-31 | -$1.82M derived: sum of 2 quarters · filed 2011-10-31 | -$10.46M 10-Q · filed 2011-10-31 | |||||
| 2010-06-30 | -$5.15M 10-Q · filed 2011-07-29 | -$13.79M 10-Q · filed 2011-07-29 | ||||||
| 2009-12-31 | -$51.04M 10-K · filed 2012-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |